Dissertations / Theses on the topic 'Utrophin'

The spectrin superfamily is a diverse group of proteins variously involved in cross- linking, bundling and binding to the F-actin cytoskeleton. These proteins are modular in nature and interaction with actin occurs, at least in part, via CH domain containing ABDs. The actin binding domains of the spectrin superfamily proteins are all very similar in overall structure however the functions of the individual proteins differ greatly. Utrophin is a member of the spectrin superfamily and has been used extensively to investigate and model the association of actin-binding domains with F- actin; however, much controversy exists as to whether binding occurs when the domain is in an open or a closed conformation. The data herein specifically investigates the importance of the utrophin ABD inter- CH domain linker to the conformation of the domain and how this domain associates with F-actin. We provide evidence that this particular region of the ABD is particularly sensitive to mutation and that the conformation of the domain when in solution cannot be altered by affecting the electrostatic environment surrounding the protein. It has been assumed previously that the utrophin ABD adopts a closed and compact configuration in solution similar to the fimbrin crystal structure conformation; however we present evidence that suggests this is not the case. It has been proposed that the utrophin ABD may open from this closed conformation to bind F-actin in a more open manner, we present data that demonstrates that opening of the domain is not essential to F-actin binding and that there is very little conformation change associated with the domain upon interaction with F-actin. It appears that the utrophin ABD can bind F actin in two conformations. This supports current models of utrophin ABD binding where interaction with F-actin occurs in either an open or closed conformation. The data presented here provides an interesting insight into the utrophin ABD/F-actin interaction and raises many questions regarding the evaluation of current binding models. Future research stemming from this work will serve to further the understanding of how utrophin and related actin-binding proteins interact with F-actin.

Understanding the regulatory mechanisms controlling utrophin A expression at the sarcolemma of dystrophic muscles will facilitate the development of therapeutic strategies to ameliorate the pathophysiological features of Duchenne Muscular Dystrophy (DMD). The main goal of this study was to characterize the regulation of utrophin A IRES activity using a transgenic mouse model expressing the utrophin A 5’UTR bicistronic reporter and to identify trans-acting factors that could mediate IRES activity and endogenous expression of utrophin A. We found that utrophin A IRES activity is specifically expressed in skeletal muscles. Moreover, we identified eEF1A2 as a muscle-specific trans-acting factor that can interact with utrophin A and mediate IRES-dependent translation of utrophin A. Finally, we showed that eEF1A2 mediates endogenous utrophin A expression and localization in skeletal muscle. Identifying pharmacological compounds that would specifically target eEF1A2 and increase endogenous levels of utrophin A expression could serve as a drug-based therapy to treat DMD.

Duchenne Muscular Dystrophy (DMD) is a disorder caused by mutations in the dystrophin gene, preventing the production of the functional dystrophin protein which assures maintenance of the myofiber integrity throughout muscle contraction. A lack of dystrophin results in severe muscle degeneration and regeneration accompanied by a loss of muscle function. Many pre-clinical and clinical studies are focused on developing strategies to counteract the detrimental effects of DMD; however, there is no cure. One such approach consists of upregulating the endogenous protein utrophin A in dystrophic muscle, which, once highly expressed at the sarcolemma, could functionally compensate for the lack of dystrophin. Recent evidence demonstrates that utrophin A expression is regulated at its 3’ and 5’UTR through post-transcriptional and translational events. Therefore, in the work presented here, we hypothesized that repurposing FDA-approved drugs that target the signaling pathways involved in post-transcriptional and translational regulation of utrophin A will be an efficient approach in rapidly bringing new therapeutic interventions for DMD. In this work, we repurposed four promising FDA-approved drugs able to stimulate utrophin A expression levels in dystrophic muscles: the anti-coagulant drug Heparin, the anti-inflammatory drug Celecoxib, the β-adrenergic receptor blocking agent Betaxolol and the cholesterol-lowering drug Pravastatin. These drugs induce significant improvements in the dystrophic phenotype of mdx mice. This includes amelioration of muscle fiber integrity and muscle function as well as promoting morphological and fiber type changes in mdx mice muscles. Collectively, this thesis describes the potential of a repurposing approach to activate key post-transcriptional and translational pathways involved in utrophin A’s regulation in the hopes of developing new therapeutics for the treatment of DMD.

Characterized by the severe progressive wastage of skeletal muscle, Duchenne muscular dystrophy (DMD) is a crippling X-linked recessive disease that is caused by the absence of the protein dystrophin. This thesis aimed to critically evaluate the potential of different therapeutic options to combat this disease. Utrophin is a paralogue of dystrophin. The Fiona mouse is an mdx (dystrophin-deficient) transgenic mouse that overexpresses the full-length utrophin protein in skeletal muscle, and various studies have shown that it does not display a dystrophic phenotype. However, these studies have only been performed on sedentary mice. In this work it is demonstrated that utrophin’s protective effect is partially diminished after a sustained period of exercise-induced stress, highlighting for the first time a functional difference between dystrophin and utrophin. This thesis also presents results of two mdx mouse drug trials testing the ameliorative effects of the administration of the drugs GW501516 and C1100, which show that treatment with both drugs results in partial amelioration of the dystrophic phenotype. GW501516 administration results in a beneficial fast-to-slow fibre type switch and an in vivo increase in utrophin protein levels. We have also shown that C1100 treatment results in a significant increase in utrophin A promoter activity in vitro, and the mechanism of action of this drug on this promoter has been deciphered. The global dysregulation of microRNAs in skeletal muscle of mdx and dko (dystrophin- and utrophin-deficient) mice was evaluated by microarray analysis to identify microRNAs involved in the dystrophic pathological cascades. The results of detailed expression analyses of miR-31, miR-206 and miR-503 are presented, and two therapeutically-relevant predicted targets of miR-503 were validated. Overall, this thesis evaluates the potential of different and possibly complementary therapeutic options to combat DMD.

Duchenne muscular dystrophy (DMD) is the most severe and prevalent primary myopathy. This disease is characterized by repeated cycles of muscle fiber degeneration and regeneration with an eventual failure to regenerate leading to the progressive replacement of myofibers by adipose and connective tissues. The genetic defects responsible for DMD are mutations in the short arm of the X chromosome which prevent the production of normal size dystrophin, a large cytoskeletal protein of 427 kDa. In contrast to the homogeneous distribution of dystrophin along muscle fibers, utrophin preferentially accumulates at the neuromuscular junction. Due to this sequence similarity between dystrophin and utrophin, it has been suggested that increased expression of utrophin into extrasynaptic regions of dystrophic muscle fibers may represent a therapeutic strategy for DMD. Recently, it has been confirmed that the upregulation of utrophin can, indeed, functionally compensate for the lack of dystrophin and alleviate the muscle pathology. In this context, it thus becomes essential to determine the cellular and molecular mechanisms presiding over utrophin expression in attempts to overexpress the endogenous gene product throughout skeletal muscle fibers. In this Thesis, I explore the mechanisms underlying the selective accumulation of utrophin at the postsynaptic membrane of the neuromuscular synapse. We determined by in situ hybridization that local transcription contributes to the accumulation of utrophin at the neuromuscular junction. Using direct injections of utrophin promoter-reporter constructs into skeletal muscle, we also defined the promoter elements involved in this local transcription and determined that the N-box element is a key consensus sequence that directs transcriptional control of utrophin expression at the neuromuscular junction. Furthermore, additional experiments revealed that utrophin gene transcription is dependent on the extracellular matrix proteins agrin and ARIA/heregulin, and this regulation is dependent upon the N-box element. Indeed, in vitro transfection assays and electromobility shift assays indicated that agrin and ARIA/heregulin may ultimately initiate a cell signaling cascade that activates the ETS-related transcription factor, GA-binding protein (GABP) which binds and activates the N-box element. In these experiments, we determined by RT-PCF, immunoblotting, and nuclear run on assays that, in contrast to the large changes in AChR, utrophin expression was only marginally increased under these conditions. (Abstract shortened by UMI.)

Duchenne Muscular Dystrophy (DMD) is an X-linked recessive neuromuscular disorder caused by mutations or deletions in the dystrophin gene. Utrophin up-regulation therapy is among the various therapeutic strategies that are being investigated to treat DMD. In this strategy utrophin, a dystrophin homologue, is up-regulated along the entire length of the sarcolemma to replace the absent dystrophin protein. Previous studies have revealed that utrophin A expression can be controlled by various transcriptional, post-transcriptional and translational mechanisms and pharmacological modulation of these pathways can stimulate its expression in muscle. In the present study we screened several FDA approved and natural pharmacological compounds that can potentially activate utrophin A expression in muscle. We found that AICAR (AMPK activator) and heparin (p38 activator) were most effective in stimulating utrophin A expression in our C2C12 muscle cell system. Next, we analyzed the effect of combining these activators on utrophin A expression in muscle cells and preclinical mdx mouse model of DMD. Our findings revealed that combinatorial treatment of AICAR and heparin instigated an additive effect on utrophin A expression both in C2C12 muscle cells and mdx mice. Further characterization of treated mdx mice revealed that combinatorial treatment of AICAR and heparin caused improvements in the dystrophic phenotype as indicated by decreased central nucleation, decreased fiber size variability and improved sarcolemmal integrity in dystrophic muscle. Together these findings established that combinatorial treatment of AICAR and heparin ameliorates the dystrophic phenotype in mdx mice and may serve as an effective therapeutic strategy for DMD.

Duchenne Muscular Dystrophy (DMD) results from the absence of a functional dystrophin protein. Among its possible therapeutic options is the upregulation of dystrophin’s autosomal analogue, utrophin A. This can be achieved by a pharmacologically induced shift towards a slower, more oxidative skeletal muscle phenotype, which has been shown to confer morphological and functional improvements on models of DMD. Whether these improvements are a result of the utrophin A upregulation or other beneficial adaptations associated with the slow, oxidative phenotype, such as improved autophagy, has not been determined. To understand the importance of utrophin A to the therapeutic value of the slow, oxidative phenotype, we used the utrophin/dystrophin double knockout (dKO) model of DMD. We found the dKO mouse to have a similar skeletal muscle signaling capacity and phenotype to mdx mice. When treated with the adenosine monophosphate activated protein kinase (AMPK) agonist 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR), both dKO and mdx mice expressed a shift towards a slower, more oxidative phenotype. In the mdx mice, this shift caused improvements in muscle fiber central nucleation, IgM penetration, damage from eccentric contractions, and forelimb grip strength. These morphological and functional benefits were not seen in the AICAR treated dKO mice. This study highlights the importance of utrophin A upregulation to the benefits of the slow, oxidative myogenic program to dystrophic mice. It confirms utrophin A as a therapeutic target in DMD and the slow, oxidative myogenic program as clinically relevant avenue towards treatment of the disease.

Duchenne muscular dystrophy (DMD) is a severe and fatal muscle wasting disease characterized by a high mutation rate in the gene that encodes the membrane-associated protein dystrophin that results in absence of expressed protein. Although the primary genetic defect for DMD is known, the mechanisms that initiate the onset of DMD are not currently understood. This study tested the hypothesis that pathophysiological processes involved in DMD could be identified by the global expression of mRNA in maturing dystrophin- and utrophin-deficient mouse (mdx:utrn-/-) muscles. Two potential dystrophic onset mechanisms targeted for analysis were (1) disrupted expression of calcium handling proteins; and, (2) increased expression of immune response markers. An mRNA expression profile was developed following isolation of total RNA from control and mdx:utrn-/- triceps surae (TS) muscles at ages 9-10 and 20-21 days using Affymetrix® Mu74Av2 GeneChips®. Compared to control, the mRNA expression profile in mdx:utrn-/- muscles revealed there was a 3-fold increase in the number of gene transcripts differentially expressed more than 2-fold (53 transcripts at ages 9-10 days; 153 at ages 20-21 days). However, there were no changes in the mRNA transcripts for calcium handling proteins. In distinct contrast, there was up-regulation of transcripts that corresponded to an immune response (40 transcripts), extracellular matrix activity (14), and proteolysis (8). Up-regulation of several transcripts corresponded to cytokines and their receptors (11), chemokines and their receptors (5), and lymphoid and myeloid markers (16) suggesting that dystrophic muscle is susceptible to invasion by macrophages, leukocytes, B- and T-cells. These results are consistent with several reports (Spencer et al., 1997; Chen et al., 2000; Porter et al., 2002; Porter et al., 2003a; Porter et al., 2003b; Porter et al., 2004) that indicate the immune system may play an important role in the early pathophysiology of DMD. Understanding the functional aspects of an immune response in DMD onset should lead to more effective therapeutics.
Master of Science

Up-regulating utrophin expression at the sarcolemma is thought to be a key therapeutic approach in the fight against DMD. Utrophin was found to have two isoforms which differ mainly in their 5'-untranslated regions. Effects of the utrophin 5'UTRs on reportergene expression in cell culture and muscle injection experiments were assayed by measuring both reporter transcript and protein levels. Translation efficiencies were estimated by calculating transcript to protein ratios. Our results indicate that there is considerable translation inhibition in control muscle. In comparison, significantly divergent translation efficiencies in regenerating muscle indicate a direct correlation between transcript and protein levels, as seen in cell culture. Furthermore, low levels of translational inhibition are present in adult mdx mice, yet it is significantly de-repressed in young mdx muscle. Taken together, our results suggest that, via the utrophin 5'UTRs, translational regulation is involved in regulating utrophin expression.

The trafficking of insulin secretory granules(SGs) of pancreatic b-cells is a tightly controlled complex network. Increasing evidence indicates that the cortical actin cytoskeleton modulates the mobility and exocytosis of SGs,yet the mechanisms anchoring SGs to the cytoskeleton is not completely understood.It has been shown by Ort et al.(2000,2001) that the cytoplasmic tail of an intrinsic membrane protein of the SGs named ICA512/IA-2 binds the PDZ domain of b2-syntrophin,which in turn binds to the F-actin-binding protein utrophin. These data also indicate that stimulation of SG exocytosis affects the phosphorylation of b2-syntrophin,hence altering its binding to ICA512.Therefore a model was proposed whereby SGs are anchored to the actin cytoskeleton through the ICA512/b2-syntrophin complex, whose dynamics are regulated by phosphorylation.To test this model GFP-b2-syntrophin stable INS-1 cell clones were generated.GFP-b2-syntrophin expression and localization pattern were similar to those of the endogenous protein. Electron microscopy showed that in GFP-b2-syntrophin INS-1 cells the number of SGs with a pear-like shape was increased relative to control cells. Insulin content and stimulated secretion were increased in three GFP-â2-syntrophin INS-1 cell clones,compared to non-transfected INS-1 cells and INS-1 cells expressing GFP. These increments correlated with the different expression levels of GFP-b2-syntrophin in the three GFP-b2-syntrophin INS-1 cell clones. These findings support the hypothesis that b2-syntrophin regulates the trafficking and exocytosis of SGs by modulating their tethering to the actin cytoskeleton.In order to confirm the proposed model, the phosphorylation of b2-syntrophin was investigated in more detail. Similar to endogenous b2-syntrophin,GFP-b2-syntrophin underwent Ca2+-dependent and okadaic acid-sensitive dephosphorylation upon stimulation of insulin secretion. Stimulation-dependent dephosphorylation was confirmed by immunoprecipitation of 32P-labeled GFP-b2-syntrophin.Mass spectrometry of immunoprecipitated GFP-b2-syntrophin allowed the identification of four serine-phosphorylation sites (S75,S90,S213,S373) that could affect the binding to ICA512.Mutants,in which all four phosphoserines, were replaced by either asp or ala to mimic(S/D) or prevent(S/A) phosphorylation were expressed in INS-1 cells. All S/D mutants retained a cortical localization,but by immunoblotting the pattern of the S75D allele differed from wild type and all other S/D alleles.Conversely, all S/A alleles were diffused cytosolically, except S213A,which was still restricted to the cortex. Finally, pull down assays showed increased binding of ICA512 to the S75A and S90D alleles compared to wild type b2-syntrophin,while the opposite was observed with the S75D and S90A mutants.Additionally,both the S75 and the S213 allele conform a consensus for phosphorylation by Cdk5,which is known to modulate insulin secretion. The phosphorylation of GFP-b2-syntrophin and particularly the S75 allele by Cdk5 was exhibited with pharmacological inhibitors,by in vitro phosphorylation and by RNAi. Taken together, these findings are consistent with the model by which phosphorylation of b2-syntrophin modulates the tethering of SGs to the cytoskeleton, and thereby their mobility and exocytosis. Specifically, the data of this thesis suggest that Cdk5-dependent phosphorylation of the S75 site of GFP-b2-syntrophin facilitates insulin secretion by reducing the interaction of b2-syntrophin with ICA512,thereby decreasing the actin cytoskeleton constrain on SG mobility. This process could occur in combination with the phosphatase-dependent dephosphorylation of b2-syntrophin at phosphosites other than S75
Der Transport Insulin-gefüllter sekretorische Granula(SG) ist ein streng kontrollierter komplexer Prozess.Es gibt vermehrt Beweise,dass das kortikale Actinzytoskelett die Ausschüttung der SGs beeinflusst.Bisher ist der Mechanismus der Verankerung von SGs am Zytoskelett noch nicht vollständig aufgeklärt.Ort et al.(2000,2001) haben gezeigt,daß der zytosoplasmatische Teil des trans-membranen SG-Proteins ICA512 mit der PDZ-Domäne von b2-Syntrophin interagiert.Dieses Protein bindet das F-Actin-Bindeprotein Utrophin.Die Ergebnisse zeigen außerdem,daß durch Stimulation der SG-Exozytose der Phosphorilierungsstatus von b2-Syntrophin beeinflusst wird,woraus ein verändertes Bindungsvermögen zu ICA512 resultiert.Es wurde ein Funktionsmodel vorgestellt,in dem sich SGs durch die Interaktion des ICA512/b2-Syntrophin Komplexes an das Actinzytoskelett binden.Dabei wird die Bindedynamik durch Phosphorilierung reguliert.Um dieses Model zu etablieren,wurden stabile GFP-b2-Syntrophin produzierende INS-1-Zellklone erzeugt.Die zelluläre Lokalisation und das Expressionsmuster von GFP-b2-Syntrophin stimmen mit dem des endogenen Proteins überein.Elektronenmikroskopie zeigte eine größe Anzahl oval-verformter SGs in GFP-b2-Syntrophin INS-1-Zellen im Vergleich zu Kontrollzellen.Verglichen mit nicht-transfizierten INS-1 Zellen waren in drei GFP-b2-Syntrophin INS-1-Zellklonen der Insulingehalt der Zellen und die stimulierte Insulinsekretion erhöht.Die Werte korrelierten mit den unterschiedlichen GFP-b2-Syntrophin Expressionsmengen der Klone.Diese Ergebnisse untermauern die Hypothese,daß b2-Syntrophin den Transport und die Sekretion der SGs durch Modulation ihres Bindevermögens an Actin reguliert.Um das postulierte Model genauer zu prüfen,wurde die Phosphorilierung von b2-Syntrophin detaillierter untersucht.Das GFP-Protein wurde,ähnlich dem endogenen b2-Syntrophin,durch Stimulation der Insulinausschüttung dephosphoriliert.Diese Dephosphorilierung ist Ca2+-abhängig und Okadeinsäuresensitiv.Die stimulationsabhängige Dephosphorilierung wurde durch Immunoprezipitation von 32P-markiertem GFP-b2-Syntrophin bestätigt.Massenspektrometrie des präzipitierten Proteins ermöglichte die Identifikation von vier Serin-Phosphorilierungsstellen(S75,S90,S213,S373),welche die Bindung zu ICA512 beeinflussen könnten.Mutanten,in denen die vier Phosphoserine durch Asp beziehungsweise Ala ersetzt wurden,um entweder eine Phosphorilierung(S/D) oder Dephosphorilierung(S/A) nachzuahmen,wurden in INS-1-Zellen exprimiert.Alle S/D Mutanten blieben kortikal lokalisiert.Das Expressionsmuster des S75D Allels unterschied sich jedoch von denen des Wild-Typs(wt).Im Gegensatz dazu waren alle S/A Allele zytosolisch verteilt.Eine Ausnahme bildete S213A,das an der Zellkortex lokalisiert blieb.Im Vergleich zu wt b2-Syntrophin zeigten PullDown-Assays eine erhöhte Bindung von ICA512 zu den S75A und S90D Allelen.Das Gegenteil konnte für die S75D und S90A Mutanten nachgewiesen werden.S75,S90 und S213 sind in einer Konsensussequenz für Cdk5-Phosphorilierung enthalten.Diese Kinase kann die Insulinsekretion regulieren.Die Phosphorilierung von b2-Syntrophin,insbesondere des S75 Allels durch Cdk5 wurde durch pharmakologische Inhibitoren,in vitro-Phosphorilierung und RNAi demonstriert.Zusammenfassend stimmen diese Erkenntnisse mit dem Model überein,daß die Phosphorilierung von b2-Syntrophin die Vernetzung von SGs mit Actin und dadurch deren Mobilität und Exozytose moduliert.Im Speziellen postulieren die Ergebnisse dieser Arbeit eine Cdk5-abhängige Phosphorilierung der S75 Stelle des b2-Syntrophins.Durch eine verminderte Interaktion von b2-Syntrophin und ICA512 erleichtert diese Mutante vermutlich die Insulinsekretion,da der Einfluss des Actinzytoskeletts auf die Granulamobilität vermindert ist.Dieser Prozess ereignet sich möglicherweise in Kombination mit einer Dephosphorilierung des b2-Syntrophins.in Kombination mit einer Dephosphorilierung des b2-Syntrophins

The trafficking of insulin secretory granules(SGs) of pancreatic b-cells is a tightly controlled complex network. Increasing evidence indicates that the cortical actin cytoskeleton modulates the mobility and exocytosis of SGs,yet the mechanisms anchoring SGs to the cytoskeleton is not completely understood.It has been shown by Ort et al.(2000,2001) that the cytoplasmic tail of an intrinsic membrane protein of the SGs named ICA512/IA-2 binds the PDZ domain of b2-syntrophin,which in turn binds to the F-actin-binding protein utrophin. These data also indicate that stimulation of SG exocytosis affects the phosphorylation of b2-syntrophin,hence altering its binding to ICA512.Therefore a model was proposed whereby SGs are anchored to the actin cytoskeleton through the ICA512/b2-syntrophin complex, whose dynamics are regulated by phosphorylation.To test this model GFP-b2-syntrophin stable INS-1 cell clones were generated.GFP-b2-syntrophin expression and localization pattern were similar to those of the endogenous protein. Electron microscopy showed that in GFP-b2-syntrophin INS-1 cells the number of SGs with a pear-like shape was increased relative to control cells. Insulin content and stimulated secretion were increased in three GFP-â2-syntrophin INS-1 cell clones,compared to non-transfected INS-1 cells and INS-1 cells expressing GFP. These increments correlated with the different expression levels of GFP-b2-syntrophin in the three GFP-b2-syntrophin INS-1 cell clones. These findings support the hypothesis that b2-syntrophin regulates the trafficking and exocytosis of SGs by modulating their tethering to the actin cytoskeleton.In order to confirm the proposed model, the phosphorylation of b2-syntrophin was investigated in more detail. Similar to endogenous b2-syntrophin,GFP-b2-syntrophin underwent Ca2+-dependent and okadaic acid-sensitive dephosphorylation upon stimulation of insulin secretion. Stimulation-dependent dephosphorylation was confirmed by immunoprecipitation of 32P-labeled GFP-b2-syntrophin.Mass spectrometry of immunoprecipitated GFP-b2-syntrophin allowed the identification of four serine-phosphorylation sites (S75,S90,S213,S373) that could affect the binding to ICA512.Mutants,in which all four phosphoserines, were replaced by either asp or ala to mimic(S/D) or prevent(S/A) phosphorylation were expressed in INS-1 cells. All S/D mutants retained a cortical localization,but by immunoblotting the pattern of the S75D allele differed from wild type and all other S/D alleles.Conversely, all S/A alleles were diffused cytosolically, except S213A,which was still restricted to the cortex. Finally, pull down assays showed increased binding of ICA512 to the S75A and S90D alleles compared to wild type b2-syntrophin,while the opposite was observed with the S75D and S90A mutants.Additionally,both the S75 and the S213 allele conform a consensus for phosphorylation by Cdk5,which is known to modulate insulin secretion. The phosphorylation of GFP-b2-syntrophin and particularly the S75 allele by Cdk5 was exhibited with pharmacological inhibitors,by in vitro phosphorylation and by RNAi. Taken together, these findings are consistent with the model by which phosphorylation of b2-syntrophin modulates the tethering of SGs to the cytoskeleton, and thereby their mobility and exocytosis. Specifically, the data of this thesis suggest that Cdk5-dependent phosphorylation of the S75 site of GFP-b2-syntrophin facilitates insulin secretion by reducing the interaction of b2-syntrophin with ICA512,thereby decreasing the actin cytoskeleton constrain on SG mobility. This process could occur in combination with the phosphatase-dependent dephosphorylation of b2-syntrophin at phosphosites other than S75.
Der Transport Insulin-gefüllter sekretorische Granula(SG) ist ein streng kontrollierter komplexer Prozess.Es gibt vermehrt Beweise,dass das kortikale Actinzytoskelett die Ausschüttung der SGs beeinflusst.Bisher ist der Mechanismus der Verankerung von SGs am Zytoskelett noch nicht vollständig aufgeklärt.Ort et al.(2000,2001) haben gezeigt,daß der zytosoplasmatische Teil des trans-membranen SG-Proteins ICA512 mit der PDZ-Domäne von b2-Syntrophin interagiert.Dieses Protein bindet das F-Actin-Bindeprotein Utrophin.Die Ergebnisse zeigen außerdem,daß durch Stimulation der SG-Exozytose der Phosphorilierungsstatus von b2-Syntrophin beeinflusst wird,woraus ein verändertes Bindungsvermögen zu ICA512 resultiert.Es wurde ein Funktionsmodel vorgestellt,in dem sich SGs durch die Interaktion des ICA512/b2-Syntrophin Komplexes an das Actinzytoskelett binden.Dabei wird die Bindedynamik durch Phosphorilierung reguliert.Um dieses Model zu etablieren,wurden stabile GFP-b2-Syntrophin produzierende INS-1-Zellklone erzeugt.Die zelluläre Lokalisation und das Expressionsmuster von GFP-b2-Syntrophin stimmen mit dem des endogenen Proteins überein.Elektronenmikroskopie zeigte eine größe Anzahl oval-verformter SGs in GFP-b2-Syntrophin INS-1-Zellen im Vergleich zu Kontrollzellen.Verglichen mit nicht-transfizierten INS-1 Zellen waren in drei GFP-b2-Syntrophin INS-1-Zellklonen der Insulingehalt der Zellen und die stimulierte Insulinsekretion erhöht.Die Werte korrelierten mit den unterschiedlichen GFP-b2-Syntrophin Expressionsmengen der Klone.Diese Ergebnisse untermauern die Hypothese,daß b2-Syntrophin den Transport und die Sekretion der SGs durch Modulation ihres Bindevermögens an Actin reguliert.Um das postulierte Model genauer zu prüfen,wurde die Phosphorilierung von b2-Syntrophin detaillierter untersucht.Das GFP-Protein wurde,ähnlich dem endogenen b2-Syntrophin,durch Stimulation der Insulinausschüttung dephosphoriliert.Diese Dephosphorilierung ist Ca2+-abhängig und Okadeinsäuresensitiv.Die stimulationsabhängige Dephosphorilierung wurde durch Immunoprezipitation von 32P-markiertem GFP-b2-Syntrophin bestätigt.Massenspektrometrie des präzipitierten Proteins ermöglichte die Identifikation von vier Serin-Phosphorilierungsstellen(S75,S90,S213,S373),welche die Bindung zu ICA512 beeinflussen könnten.Mutanten,in denen die vier Phosphoserine durch Asp beziehungsweise Ala ersetzt wurden,um entweder eine Phosphorilierung(S/D) oder Dephosphorilierung(S/A) nachzuahmen,wurden in INS-1-Zellen exprimiert.Alle S/D Mutanten blieben kortikal lokalisiert.Das Expressionsmuster des S75D Allels unterschied sich jedoch von denen des Wild-Typs(wt).Im Gegensatz dazu waren alle S/A Allele zytosolisch verteilt.Eine Ausnahme bildete S213A,das an der Zellkortex lokalisiert blieb.Im Vergleich zu wt b2-Syntrophin zeigten PullDown-Assays eine erhöhte Bindung von ICA512 zu den S75A und S90D Allelen.Das Gegenteil konnte für die S75D und S90A Mutanten nachgewiesen werden.S75,S90 und S213 sind in einer Konsensussequenz für Cdk5-Phosphorilierung enthalten.Diese Kinase kann die Insulinsekretion regulieren.Die Phosphorilierung von b2-Syntrophin,insbesondere des S75 Allels durch Cdk5 wurde durch pharmakologische Inhibitoren,in vitro-Phosphorilierung und RNAi demonstriert.Zusammenfassend stimmen diese Erkenntnisse mit dem Model überein,daß die Phosphorilierung von b2-Syntrophin die Vernetzung von SGs mit Actin und dadurch deren Mobilität und Exozytose moduliert.Im Speziellen postulieren die Ergebnisse dieser Arbeit eine Cdk5-abhängige Phosphorilierung der S75 Stelle des b2-Syntrophins.Durch eine verminderte Interaktion von b2-Syntrophin und ICA512 erleichtert diese Mutante vermutlich die Insulinsekretion,da der Einfluss des Actinzytoskeletts auf die Granulamobilität vermindert ist.Dieser Prozess ereignet sich möglicherweise in Kombination mit einer Dephosphorilierung des b2-Syntrophins.in Kombination mit einer Dephosphorilierung des b2-Syntrophins.

A Distrofia Muscular de Duchenne (DMD) é uma importante e severa doença músculo degenerativa causada pela mutação do gene da distrofina. Na ausência da distrofina, o sarcolema das células torna-se vulnerável devido a danos induzidos por ciclos contínuos de degeneração e regeneração. Consequentemente, a força muscular diminui e as miofibras são substituídas por tecido fibrótico. Dentre os músculos esqueléticos afetados, o diafragma, destaca-se por ser o principal músculo respiratório acometido na DMD. Similarmente a DMD humana, o modelo mdx, apesar de exibir um fenótipo suave, este apresenta um severo acometimento no músculo diafragma, assim como observado em nosso estudo prévio, aqui descritos. Entretanto, este é considerado um modelo pobre, porque ele não consegue reproduzir, o fenótipo severo observado nos pacientes. O camundongo mdx/utrn+/- (dystrophin-null heterozygous urtrophin mice) com haploinsuficiência da utrofina, tem sido hipotetizado como um modelo com um fenótipo intermediário, ganhando popularidade nos laboratórios. Porém, infelizmente, até os dias de hoje, não existe evidências fisiológicas e funcionais suficientes que justifiquem a escolha deste modelo para as terapias experimentais. Portanto, neste estudo objetivou-se esclarecer a real contribuição do camundongo mdx/utrn+/- para as terapias experimentais. Para testar esta hipótese, elegeu-se analisar a morfologia e a função muscular do músculo diafragma do mdx e mdx/utrn+/- com 2 e 6 meses de idade. Para elucidar a morfopatologia do diafragma foi utilizado microscopia de luz e análises de imunohistoquímica. A função muscular do diafragma foi analisada através da avaliação das propriedades contráteis e passivas. A forma de como executar a função muscular do diafragma foi atualizada através da criação de dois clips, os quais permitiram avaliar o músculo de forma segura. A adaptação de um novo protocolo de avaliação da função muscular mostrou-se eficaz e capaz de ser utilizada para avaliar as propriedades contráteis e passivas. Aos 2 meses de idade, as colorações de Hematoxilina e eosina, Tricômio de Masson e Alizarina vermelha revelaram que o mdx/utrn+ apresentou maior quantidade de infiltrado inflamatório, tecido conectivo e áreas de calcificação do que o mdx. Já aos 6 meses de idade, não houve diferença morfológica entre o mdx e o mdx/utrn+/-. Na análise de imunohistoquímica para eMyHC (miosina embrionária de cadeia pesada eMyHC), não foi observada diferença entre o mdx e o mdx/utrn+/-aos 2 e 6 meses de idade. Entretanto, os resultados obtidos em ambas as idades, demonstraram a presença de regeneração muscular. Na marcação da proteína distrofina e utrofina, as células inflamatórias e os tipos de fibras musculares também foram detectados por imunohistoquímicas. A marcação da proteína distrofina, mostrou-se ausente no mdx e mdx/utrn+/- com 2 e 6 meses de idade. A marcação da proteína utrofina mostrou-se mais evidente no mdx do que no mdx/utrn+/-, videnciando a haploinsuficiência nos mdx/utrn+/-. Macrófagos foram encontrados em maior quantidade no camundongo mdx/utrn+/- com 2 e 6 meses do que no mdx, mostrando que o processo de inflamação encontrou-se aumentado nos mdx/utrn+/- Neutrófilos encontraram-se aumentados no mdx/utrn+/- com 2 meses, evidenciando a fase aguda da inflamação. Entretanto nos animais de 6 meses, quantidades semelhantes de neutrófilos foram detectadas no mdx/utrn+/- e mdx. Fibras marcadas pelas isoformas MyHC- I, IIa e IIx foram detectadas em maior porcentagem no BL10 do que no mdx e mdx/utrn+/- aos 2 meses de idade, demonstrando que a diminuição destas, no mdx e mdx/utrn+/- pode colaborar para a diminuição da força nestes animais. Aos 6 meses, porcentagem similares de MyHC- I foram detectadas no BL10, mdx e mdx/utrn+/-. MyHC-IIa não foram encontradas nos animais de 6 meses. MyHC-IIx encontraram-se em maior porcentagem no BL10 do que no mdx e mdx/utrn+/- com 6 meses de idade. Baixa porcentagem de isoformas de MyHC- I/IIa foram detectadas no mdx e mdx/utrn+/- aos 2 e 6 meses de idade e encontraram-se ausentes no BL10 de mesma idade. Fibras marcadas pela isoformas MyHC-IIa/IIx apresentaram-se aumentadas no mdx e mdx/utrn+/- aos 2 e 6 meses, podendo este aumento auxiliar na manutenção da força muscular. MyHC-IIx-IIb foram detectadas em maior porcentagem no mdx, reduzidas no BL10 e ausentes no mdx/utrn+/- com 2 meses de idade. Estas não foram identificadas nos animais de 6 meses. As propriedades contráteis do camundongo mdx/utrn+/- aos 2 meses de idade apresentaram-se mais comprometidas do que no mdx. Pt (contração isométrica máxima), sPt (força específica de Pt), Po (Força tetânica máxima) e sPo (força específica de Po) exibiram-se mais afetadas no mdx/utrn+/- do que no mdx. Porém aos 6 meses de idade não houve diferença significativa de força entre o mdx/utrn+/- e o mdx. As propriedades passivas do mdx/utrn+/- com 2 meses apresentou mais acometida do que no mdx. Entretanto, aos 6 meses, esta propriedade não se diferenciou entre o mdx/utrn+/- e o mdx. Em suma, conclui-se que o mdx/utrn+/- representa um modelo superior ao mdx com 2 meses de idade, uma vez que este apresentou morfologia, propriedades contráteis e passiva mais comprometidas do que no mdx. Aos 6 meses as propriedades contráteis e passivas e morfológicas do camundongo mdx/utrn+/- não se diferenciou do mdx. Sugerimos que o uso do mdx/utrn+/- com 2 meses de idade pode potencializar os testes pré-clinicos
Duchenne Muscular Dystrophy (DMD) is an important and severe muscle wasting disease caused by a dystrophin mutation. In the absence of dystrophin, sarcolemma becomes vulnerable to damage due a damage caused by continuous cycles of degeneration regeneration. Consequently, the muscle force reduces and the myofibers are replaced by fibrotic tissue. Between the skeletal muscles, the diaphragm is main affected muscle in DMD. Similarly, to a human DMD, despite the mdx model exhibit a milder phenotype, he presents the diaphragm muscle severely affected, as it was observed in our previous study, here described. However, it is also considered a poor model because it cannot reproduce the severe dystrophic phenotype seen in patients. An utrophin heterozygous utrophin mice (mdx/utrn+/- ), has been hypothesized as an intermediate model and they are gaining popularity in many laboratories. However unfortunately there is currently, no physiological enough evidence to justify the choice of this model for experimental therapies. Therefore, in this study, we aimed to elucidate the real contribution of the mdx/utrn+/- for the experimental therapies. To test this hypothesis, we evaluated the diaphragm muscle morphology and muscle function of the mdx and mdx/utrn+/- with 2 and 6 months. To elucidate the diaphragm morphology, we used light microscopy techniques and immunostaining analysis. Muscle function was evaluated through the active and passive properties. The clamps allowed to safe evaluate the diaphragm function. The update of the new protocol was efficient and able to evaluate the active and passive properties. At 2 months, the Hematoxylin and eosin, Masson Thrichome, Alisarine red, revealed that the mdx/utrn+ showed more inflammatory infiltrate, connective tissue and more areas with calcification than mdx model. At 6 months, there was no significant differences between mdx and mdx/utrn+. In the immunohistochemical analysis for eMyHC (embryonic myosin heavy chain), there was no difference between mdx and mdx/utrn+/- at 2 and 6 months. However, the results obtained in both ages, showed muscle regeneration Marking for dystrophin and utrophin protein, inflammatory cells and fiber type were also detected by immunohistochemistry. Marking for dystrophin was absent in mdx and mdx/utrn+/- with 2 and 6 months. Marking for utrophin protein was more evident in mdx than in mdx/utrn+/- mice, evidencing the utrophin haploinsufficiency in mdx/utr+/-. Macrophages were increased in mdx/utrn+/- than in mdx mice with 2 and 6 months, showing an inflammation. Neutrophils were increased in mdx/utrn+/- at 2 month-old, evidencing the acute phase of inflammation. However, at 6 months similar amounts of neutrophil were detected in mdx and mdx/utrn+/-. Fibers marked by MyHC-I, IIa and IIx were detected in a higher percentage in BL10 than in mdx and mdx/utrn+/- at 2 months, showing that this change could collaborate with force decrease in these animals. At 6 months, similar percentage of MyHC-I was detected in BL10, mdx and mdx/utrn+/-. MyHC-IIa animals were not found at 6 months. Higher percentage of MyHC-IIx was found in BL10 than in mdx and mdx/utrn+/- with 6 months. Low percentage of MyHC- I/IIa was detected in mdx and mdx/utrn+/- at 2 and 6 months and it was absent in BL10 in the same age. Fibers marked by MyHC-IIa/IIx isoforms were increased in mdx and mdx/utrn+/- with 2 and 6 months. These changes could help to maintain the muscle force. MyHC-IIx-IIb was detected in higher percentage in mdx, reduced the BL10 and it was absent in mdx/utrn+/- with 2 months. MyHC-IIx-IIb was not identified in the animals with 6 months. Contractile properties in mdx/utrn+/- at 2 months were more affected than in mdx mice. Pt (maximal twitch force), sPt (specific twitch force), Po (maximal tetanic force) and sPo (specific tetanic force) showed more severely affected in mdx/utrn+/- than in mdx mice. At 6 months there were no significant difference in Pt, sPt, Po and sPo between mdx/utrn+/- and mdx mice. Passive properties of mdx/utrn+/- with 2 months presented more affected than the in mdx mice. However, at 6 months, this property did not differ between mdx/utrn+/- and mdx mice. In summary, we concluded that the mdx/utrn+/- at 2 month represent a superior model than the mdx with matched-age, since they presented morphology and contractile and passive properties more compromised than mdx mice. At 6 months, the mdx/utrn+/-contractile and the passive properties and morphology did not differ from the mdx mice age-matched. We suggest that the use of mdx/utrn+/- with 2 months-old would represent would represent a better model to test the potential of the therapies than mdx mice

The dystrophinopathies are a group of disorders characterised by cellular absence of the membrane stabilising protein, dystrophin. Duchenne muscular dystrophy is the most severe disorder clinically. The deficiency of dystrophin, in the muscular dystrophy X-linked (mdx) mouse causes an elevation in intracellular calcium in cardiac myocytes. Potential mechanisms contributing to increased calcium include enhanced influx, sarcoplasmic reticular calcium release and\or reduced sequestration or sarcolemmal efflux. This dissertation examined the potential mechanisms that may contribute to an intracellular calcium overload in a murine model of muscular dystrophy. The general cardiomyopathy of the mdx myocardium was evident, with the left atria from mdx consistently producing less force than control atria. This was associated with delayed relaxation. The role of the L-type calcium channels mediating influx was initially investigated. Dihydropyridines had a lower potency in contracting left atria corresponding to a redued dihydropyridine receptor affinity in radioligand binding studies of mdx ventricular homogenates (P<0.05). This was associated with increased ventricular dihydropyridine receptor protein and mRNA levels (P<0.05). The function of the sarcoplasmic reticulum in terms of release and also sequestration of calcium via the sarco-endoplasmic reticulum ATPase were investigated. A lower force of contraction was evident in mdx left atria in response to a range of stimulation frequencies (P<0.05) and concentrations of extracellular calcium (P<0.05). However, in the presence of 1 nM Ryanodine to block sarcoplasmic reticular calcium release, increased stimulation frequency caused similar forces to those obtained in control mice suggesting enhanced calcium influx via L-type calcium channels in mdx. Rapid cooling contractures showed a reduced contracture in mdx compared to control in response to cooling. This suggests some dysfunction in SR storage, which may be associated with the delayed relaxation time. Concentration-response curves to inhibitors of the sarco-endoplasmic reticulum showed no difference in function of the enzyme responsible for calcium uptake into the sarcoplasmic reticulum. Although sarco-endoplasmic reticulum ATPase mRNA was upregulated, no functional benefit was evident. This study indicates that a deficiency of dystrophin leads to upregulation of L-type calcium channels that contribute to increased calcium influx, with no functional change in sarcoplasmic reticular sequestration. Upregulation of the influx pathway is a potential mechanism for the calcium overload observed in mdx cardiac muscle.

Duchenne Muscular Dystrophy (DMD) is an x-linked neuromuscular disease that is caused by an absence of dystrophin protein, rendering skeletal muscle more susceptible to contraction-induced damage. One therapeutic strategy focuses on increasing the expression of endogenous utrophin A, a dystrophin homologue. Interestingly, slow muscle is more resistant to the dystrophic pathology and has increased utrophin A expression (Webster 1998; Gramolini 2001b). These observations led researchers to explore the therapeutic potential of stimulating the slow, oxidative myogenic program (SOMP) in the mdx context. Beneficial adaptations were seen with pharmacological activation of PPARδ and AMPK. We treated mdx mice with resveratrol (~100mg/kg/day), a putative SIRT1 activator, for 6-7 weeks and evaluated the activity of phenotypic modifiers that are known to influence the SOMP. SIRT1 activity and protein levels increased significantly, as well as downstream PGC-1α activity. There was evidence of a fibre type conversion as the treated mice had a higher proportion of the slow myosin heavy chain isoforms in both the EDL and Soleus skeletal muscles. Utrophin A protein levels showed modest, but consistent increases with resveratrol treatment. Finally, histological analysis revealed improvements in central nucleation and fibre size variability. These findings were promising, but raised the question of whether modifying the treatment regimen may result in greater therapeutic benefits. Surprisingly, we discovered that an elevated dose of 500mg/kg/day was ineffective in its promotion of the SOMP. SIRT1 was not activated and there was no change in utrophin A levels with resveratrol treatment. Taken together, this study demonstrates that resveratrol has the ability to promote the SOMP through SIRT1 and PGC-1α activation. It also highlights the importance of selecting an appropriate dose of resveratrol to maximize its effectiveness.

Duchenne Muscular Dystrophy (DMD) is a fatal condition occurring in approximately 1 in 3500 male births and is due to the lack of a protein called dystrophin. Initially DMD was considered a skeletal myopathy, but the pathology and consequences of cardiomyopathy are being increasingly recognised. Fibrosis, resulting from continual cycles of degeneration of the muscle tissues followed by inadequate regeneration of the muscles, is progressive in both cardiac and skeletal dystrophic muscle. In the heart fibrosis interferes with contractility and rhythm whereas it affects contractile function and causes contractures in skeletal muscles. This study utilised the mdx mouse which exhibits a pathological loss of muscle fibres and fibrosis characteristic of DMD, to examine a range of mechanisms that can influence muscle function and fibrosis. Ageing and workload both appear to contribute to the development of dystrophic features in cardiac and skeletal muscle of the mdx mouse. Therefore the effect of eccentric exercise on cardiac and skeletal muscle was examined in older mdx mice. Mice ran in 30 minute sessions for five months, 5 days per week. Downhill treadmill running did not exacerbate the contractile function or fibrosis of the mdx heart or the EDL, SOL or diaphragm muscles suggesting that cytokines influence function and fibrosis to a greater extent than workload alone. The role of the cytokine TGF-beta was examined by treating mdx mice with the TGF-beta antagonist pirfenidone at 0.4, 0.8 or 1.2 per cent in drinking water for six months. Pirfenidone improved cardiac contractility (P<0.01) and coronary flow (P<0.05), to levels comparable to control mice, despite no reduction in cardiac fibrosis. Pirfenidone did not reduce fibrosis or improve function in skeletal muscle. A deficiency of neuronal nitric oxide synthase (nNOS) in DMD and mdx mice causes a lowered production of nitric oxide indicating that the substrate of nNOS, l-arginine, may be beneficial to cardiac and skeletal muscle function in mdx mice. Oral l-arginine (5 mg/g bw) improved cardiac contractility, coronary flow and reduced cardiac fibrosis (P<0.05) without improving skeletal muscle function or fibrosis. In contrast, 10 mg/g bw l-arginine improved cardiac function and coronary flow (P<0.01), despite also elevating cardiac collagen. This increment in collagen was prevented by co-administration of prednisone. The experiments described in this dissertation reveal for the first time that pharmacological treatments in mdx mice can improve cardiac structure and function. Further elucidation of the optimum time and doses of such treatments may result in future pharmacological treatments to improve cardiac function and fibrosis in DMD.

Orientador: Humberto Santo Neto
Tese (doutorado) - Universidade Estadual de Campinas, Instituto de Biologia
Made available in DSpace on 2018-08-20T21:05:12Z (GMT). No. of bitstreams: 1 Ferretti_Renato_D.pdf: 15919724 bytes, checksum: 2e3e4ba8b562aaaaf3dde85b2e810561 (MD5) Previous issue date: 2012
Resumo: Os músculos intrínsecos da laringe (MIL) são protegidos da mionecrose em camundongos mdx, modelo da distrofia muscular de Duchenne (DMD). A DMD caracteriza-se pela mionecrose, causada pela ausência da proteína distrofina (DIS). A DIS se une a um complexo glicoproteínas (CDG), que auxilia na estabilidade da fibra e interage com proteínas reguladoras do Ca2+. O sarcolema instável dado pela ausência da DIS, diminuição de proteínas do CDG, desregulação de canais de Ca2+ e leva ao influxo de Ca2+ exacerbado, associado à diminuição da homeostase do Ca2+ intracelular e capacidade do estresse oxidativa, resulta na mionecrose. A utrofina (Utrn), semelhante à proteína DIS, se conecta às proteínas do CDG, parece ter papel na agregação dos receptores de acetilcolina (AChRs) nas junções neuromusculares (JNM) e auxiliaria na proteção da mionecrose. Neste trabalho examinamos os níveis das proteínas do CDG (beta-distroglicana [b-DG], beta-sarcoglicana [b-SG] e alfa-sintrofina [a-SIN]), da Utrn, de canais de estoque do Ca2+ (SOCE; proteínas Orai e STIM1) e proteína relacionada ao estresse oxidativo na mitocôndria (PGC-1a) em MIL distróficos. Além disso, analisamos o padrão de distribuição da Utrn e AChRs nas JNM de MIL distróficos. A análise da b-DG, b-SG, a- SIN e da Utrn pela técnica de imunohistoquímica e western blotting, mostrou que nos MIL distróficos os níveis da b-DG e da Utrn são normais em MIL adultos comparados com controle. Com envelhecimento, os níveis de proteínas do CDG e Utrn são alterados em MIL distróficos e parece não estar relacionado a proteção da mionecrose. Com emprego de técnicas moleculares e bioquímicas para análise de canais de estoque do Ca2+ (Orai e STIM1) e proteína do estress oxidativo na mitocôndria (PGC-1a), foram observados níveis aumentados de STIM1, com similar aumento da proteína calmodulina (CaM), bem como aumento da expressão do PGC-1a em MIL distróficos. Músculos acometidos distróficos apresentaram diminuição na expressão destas proteínas. Utilizando imunohistoquimica e microscopia confocal, foi observado que o padrão de distribuição da Utrn e dos AChRs não se altera nas JNM de MIL mdx. Em fibras regeneradas tanto o padrão de distribuição da Utrn quanto dos AChRs mostraram-se alterados. Pode-se concluir que os MIL de camundongos mdx apresentam manutenção dos níveis normais de proteínas do CDG e da Utrn, bem como o aumento de STIM1, CaM e PGC-1a, poderiam auxiliar, pelo menos em parte, à proteção da mionecrose
Abstract: The intrinsic laryngeal muscles (ILM) are protected from myonecrosis in the mdx mouse model of Duchenne muscular dystrophy (DMD). The DMD is characterized by myonecrosis, resulting from the absence of dystrophin protein. Dystrophin links the cytoskeleton to a complex of glycoprotein, the dystrophin-glycoprotein complex (DGC), which interacts with Ca2+-dependent channels for signaling and stability of the muscle membrane. In the absence of dystrophin, the sarcolemma becomes instable due to a decrease in the DGC level, deregulation of Ca2+-dependent channels, which increase Ca2+ influx, decreased Ca2+-handling and oxidative stress capacity, that result in muscle fiber necrosis. Utrophin (Utrn), similarly to the dystrophin, conects to DGC proteins, assembles the acethylcoline receptors (AChRs) at the neuromuscular junctions (NMJ) and may play a role in dystrophic muscle sparing. In this study, we examined the levels of DGC proteins (beta-dystroglycan [b-DG], beta-sarcoglycana [b-SG], alpha-syntrophin [a-SIN]), Utrn, store-operated Ca2+ channels (SOCE; STIM1 and Orai1 proteins), and mitochondrial oxidative protein (PGC-1a) in dystrophic ILM. We also examined the distribution of Utrn and AChRs in the dystrophic ILM NMJ. Immunohistochemistry and western blotting analyses of b-DG, b-SG and a-SIN, and the Utrn showed normal levels in adult dystrophic ILM compared with adult control. In aged mice, a dramatic decrease in DGC levels was observed in all dystrophic muscles compared with control. There are age-related alterations in DGC in the ILM of mdx mice, regardless of their protection against the lack of dystrophin. Using biochemical and molecular techniques to analyze SOCE proteins and mitochondrial oxidative protein (PGC-1a), we observed increased levels of STIM1, associated with increased level of calmodulin (CaM), and increased level of PGC-1a in dystrophic ILM. Dystrophic affected muscles have decreased levels of those proteins. Using molecular and biochemical methods we observed that Utrn and AChRs are fragmented only in affected muscle fibers and remaining unchanged in dystrophic MIL. We conclude that in adult dystrophic MIL the rescue of the DGC, increased levels of STIM1, CaM and PGC-1a, may be associated, at least in part, with their protection against myonecrosis
Doutorado
Anatomia
Doutor em Biologia Celular e Estrutural

L’objectif était d’évaluer l’efficacité de thérapies développées pour traiter la dystrophie musculaire de Duchenne (DMD, due à des mutations du gène de la dystrophine) dans la restauration de déficits cognitifs associés à ce syndrome. Deux pistes thérapeutiques visant à compenser les altérations cérébrales liées à la perte de dystrophine ont été explorées chez les souris mdx, modèle de DMD. Une approche pharmacologique basée sur la surexpression de l’utrophine, homologue de la dystrophine, n’améliore pas les déficits comportementaux des souris mdx. Par contre, une intervention génique basée sur l’épissage de l’exon muté conduit à la restauration d’une dystrophine endogène et une récupération d’altérations cérébrales comme l’agrégation des récepteurs GABAA et la plasticité synaptique hippocampique. Ceci suggère un rôle de la dystrophine dans la plasticité du cerveau adulte et l’applicabilité de cette approche de thérapie génique au traitement des altérations cognitives de la DMD
Therapies have been developed to treat Duchenne muscular dystrophy (DMD, due to mutation in the dystrophin gene), but their ability to restore the cognitive deficits associated with this syndrome has not been yet studied. We explored two therapeutic approaches to compensate for the brain alterations resulting from the loss of dystrophin in the mdx mouse, a model of DMD. A pharmacological approach based on the overexpression of utrophin, a dystrophin homologue, does not alleviate the behavioural deficits in these mice. In contrast, a genetic intervention based on the splicing of the mutated exon leads to the restoration of endogenous dystrophin and a recovery of brain alterations such as the clustering of GABAA receptors and hippocampal synaptic plasticity in mdx mice. These results suggest a role for dystrophin in adult brain plasticity and indicate that this gene therapy approach is applicable to the treatment of cognitive impairments in DMD

L'analyse des différentes interactions entre les membres du complexe associés à la dystrophine (DGC) a été le centre de plusieurs études biochimiques. Le bêta-dystroglycan prend une place primordiale au sein de ce complexe du fait de son rôle de protéine d'ancrage de la dystrophine et/ou de l'utrophine. De part son homologie structurale avec la dystrophine, l'utrophine est exprimée dans le muscle des patients DMD et de la souris modèle de cette pathologie, la souris mdx. De plus en plus d'observations soulignent l'implication du bêta-dystroglycan dans des évènements de signalisation. Comme l'organisation du complexe DGC, ces évènements sont perturbés dans le muscle déficient en dystrophine. L'interaction entre le bêta-dystroglycan et l'utrophine est une association clé au niveau du sarcolemme de la fibre dystrophique. Nos travaux sont centrés sur ce couple et en particulier sur différents processus et évènements qui influencent la stabilité de cette association. A la lumière de nos résultats, confronté aux données de la littérature, nous avons montré que l'interaction entre l'utrophine et le bêta-dystroglycan est fragilisée dans le muscle dystrophique. L'existence de l'isoform court de l'utrophine Up71 dans le diaphragme de la souris mdx ainsi que dans le nerf périphérique provoque une compétition vis-à-vis de l'ancrage au bêta-dystroglycan. D'autre part, l'affinité de l'utrophine pour le bêta-dystroglycan est également fragilisée suite à l'activation du clivage du bêta-dystroglycan dans le muscle et le nerf de la souris mdx par les métalloprotéinases. L'activation de ces protéases est le résultat d'un enchaînement de plusieurs cascades impliquant principalement certaines protéines de la cascade des MAP kinases et des protéines pro-inflammatoires. Des analyses structurales de l'association utrophine/ bêta-dystroglycan, nous ont permis de mettre en évidence l'implication directe du motif ZZ de la région riche en cystéine de l'utrophine dans l'interaction avec le bêta-dystroglycan et souligne que la fragilité de l'association l'utrophine/ bêta-dystroglycan pourrait être aussi le résultat d'une différence de la régulation de ce motif dans le muscle dystrophique.

Hintergrund und Zielsetzung: DMD ist die häufigste Form der Muskeldystrophie im Kindesalter und bis heute unheilbar. Sie wird durch das Fehlen des Proteins Dystrophin verursacht, welches verschiedene Signaltransduktionswege beeinflusst. Das Anliegen der Arbeit ist die Untersuchung und Modulation von Signaltransduktionswegen, die als alternative Therapiestrategie den Verlust von Dystrophin kompensieren könnten. Experimentelle Strategie: Für die Charakterisierung von Dystrophin nachgeschalteten Prozessen wurden mRNA-Expressionsanalysen in Muskelgeweben von DMD-Patienten und einem DMD-Brüderpaar mit einem infrafamiliär unterschiedlichen Verlauf der DMD durchgeführt. Aus diesen Expressionsdaten wurde erstmalig ein Petri-Netz entwickelt, welches Dystrophin mit in diesem Zusammenhang bisher unbekannten Signaltransduktionswegen verknüpft. Das Petri-Netz wurde auf Netzwerkintegrität und –verhalten mittels Invarianten- (INA) und theoretischen Knockout- (Mauritius Maps) Analysen untersucht. Durch beide Methoden läßt sich der maßgebliche Teilsignalweg bestimmen. In diesem Signalweg wurden die Proteinaktivität und die Genexpression durch siRNA, Vektor-DNA und chemische Substanzen in humanen SkMCs moduliert. Anschließend wurden die Proliferation und die Vitalität der Zellen sowie auch die Expression auf mRNA- und Protein-Niveau untersucht. Ergebnisse: RAP2B und CSNK1A1 waren in dem DMD-Brüderpaar differentiell exprimiert und konnten erstmalig in einem neuen, komplexen Signalweg in Zusammenhang mit Dystrophin nachgeschalteten Prozessen dargestellt werden. Mittelpunkt dieses Signalweges ist die De- und Aktivierung des Transkriptionsfaktors NFATc. Seine Zielgene umfassen neben anderen den negativen Proliferationsfaktor p21, das Dystrophin homologe UTRN und den Differenzierungsfaktor MYF5. Folglich würde ein Anstieg von UTRN eine unerwünschte Reduktion der Proliferationsrate von Myoblasten implizieren. Letzteres konnte bereits nachgewiesen werden und stellte das Motiv für weitere Studien dar. Jedoch zeigten siRNA- und Vektor-DNA-Experimente, daß NFATc nicht der ausschlaggebende Faktor für diese Zielgene ist. Die Substanzen Deflazacort (DFZ) und Cyclosporin A (CsA) wurden dagegen beschrieben, die Aktivierung von NFATc zu beeinflussen. Die Ergebnisse zeigten, daß beide Substanzen die Proliferation von Myoblasten erhöhen können. Die gleichzeitige Applikation von DFZ und CsA führte zu einem Anstieg der UTRN-Expression. Schlußfolgerung: Die Modulation der Proliferation und UTRN-Expression ist unabhängig von einander möglich. Entsprechend der Grundidee der Arbeit zeichnet sich eine neue Therapiestrategie ab, welche Dystrophin nachgeschaltete Prozesse einbezieht.
Background and aim: DMD is the most common muscular dystrophy in childhood and incurable to date. It is caused by the absence of dystrophin, what influences several signal transduction pathways. The thesis is interested in the investigation and modulation of signal transduction pathways that may compensate the lack of dystrophin as an alternative therapy strategy. Experimental strategy: To study Dystrophin downstream pathways the mRNA expression of DMD patients and two DMD siblings with an intra-familially different course of DMD were analysed in muscle tissue. On the basis of these expression data a Petri net was first developed implicating signal transduction pathways and Dystrophin downstream cascades. Invariant (INA) and theoretical knockout (Mauritius Maps) analyses were applied for studying network integrity and behaviour. Both methods provide information about the most relevant part of the network. In this part modulation of protein activity and of gene expression using siRNA, vector-DNA, and chemical substances were performed on human SkMCs. Subsequently, the cells were studied by proliferation and vitality tests as well as expression analyses at mRNA and protein level. Results: RAP2B and CSNK1A1 were differently expressed in two DMD siblings, and first are part of a signal transduction pathway implicating Dystrophin downstream processes. The central point of this pathway is the de- and activation of the transcription factor NFATc. Its target genes are, among others, the negative proliferation factor p21, the Dystrophin homologue UTRN, and the differentiation factor MYF5. Consequently, an increase in UTRN implicates an undesirably reduced myoblast proliferation rate. Latter was found in DMD patients and was target for further studies. But, siRNA and vector DNA experiments showed that NFATc is not the decisive factor for the target genes. Deflazacort and cyclosporin A are known to influence the activation of NFATc. The results first showed that both substances do induce myoblast proliferation. The use of deflazacort in combination with cyclosporin A resulted in an increase of UTRN expression. Conclusion: The modulation of proliferation and UTRN-expression independently of each other is possible. According to the basic idea of this study, a new therapeutic strategy becomes apparent, which considers Dystrophin downstream processes.

La Dp71, un produit court du gène DMD (Dystrophie Musculaire de Duchenne) est une protéine intracellulaire du cytosquelette associé à la membrane et présentant le même patron d’expression que les canaux potassiques Kir4. 1 et aqueux AQP4 dans la cellule gliale de Müller (CGM) de la rétine. Nous avons identifié le complexe macromoléculaire qui se forme autour de la Dp71 et qui est responsable de la localisation et de l’agrégation des canaux Kir4. 1 et AQP4 dans la CGM. En utilisant la souris Dp71-null, nous avons pu étudier la composition du complexe se formant autour de l’utrophine en absence de la Dp71. Nous avons également étudié l’implication fonctionnelle des complexes autour de la Dp71 et de l’utrophine dans la régulation de l’homéostasie rétinienne à travers les CGM, dans un contexte normal et pathologique. Toutes ces données permettent de mieux comprendre le rôle de la Dp71 dans la distribution des canaux Kir4. 1 et AQP4 en des endroits précis de la membrane des CGM. De plus ces résultats soulignent l’importance de la Dp71 dans la modulation des caractéristiques morphologiques et fonctionnelles de la CGM en condition normale et pathologique.